Early start of highly active antiretroviral therapy (HAART) in perinatally HIV-1 infected children is the optimal strategy to prevent immunological and clinical deterioration. To date, according to EMA, only 35% of antiretroviral drugs are licenced in children < 2 years of age and 60% in those aged 2-12 years, due to the lack of adequate paediatric clinical studies on pharmacokinetics, pharmacodynamics and drug safety in children.

Off-label use of combined antiretroviral therapy, analysis of data collected by the Italian Register for HIV-1 infection in paediatrics in a large cohort of children / Chiappini, Elena; Lisi, Catiuscia; Giacomet, Vania; Erba, Paola; Bernardi, Stefania; Zangari, Paola; Di Biagio, Antonio; Taramasso, Lucia; Giaquinto, Carlo; Rampon, Osvalda; Gabiano, Clara; Garazzino, Silvia; Tagliabue, Claudia; Esposito, Susanna; Bruzzese, Eugenia; Badolato, Raffaele; Zanaboni, Domenico; Cellini, Monica; Dedoni, Maurizio; Mazza, Antonio; Pession, Andrea; Giannini, Anna Maria; Salvini, Filippo; Dodi, Icilio; Carloni, Ines; Cazzato, Salvatore; Tovo, Pier Angelo; de Martino, Maurizio; Galli, Luisa. - In: BMC INFECTIOUS DISEASES. - ISSN 1471-2334. - 22:1(2022). [10.1186/s12879-022-07026-w]

Off-label use of combined antiretroviral therapy, analysis of data collected by the Italian Register for HIV-1 infection in paediatrics in a large cohort of children

Esposito, Susanna;
2022-01-01

Abstract

Early start of highly active antiretroviral therapy (HAART) in perinatally HIV-1 infected children is the optimal strategy to prevent immunological and clinical deterioration. To date, according to EMA, only 35% of antiretroviral drugs are licenced in children < 2 years of age and 60% in those aged 2-12 years, due to the lack of adequate paediatric clinical studies on pharmacokinetics, pharmacodynamics and drug safety in children.
2022
Off-label use of combined antiretroviral therapy, analysis of data collected by the Italian Register for HIV-1 infection in paediatrics in a large cohort of children / Chiappini, Elena; Lisi, Catiuscia; Giacomet, Vania; Erba, Paola; Bernardi, Stefania; Zangari, Paola; Di Biagio, Antonio; Taramasso, Lucia; Giaquinto, Carlo; Rampon, Osvalda; Gabiano, Clara; Garazzino, Silvia; Tagliabue, Claudia; Esposito, Susanna; Bruzzese, Eugenia; Badolato, Raffaele; Zanaboni, Domenico; Cellini, Monica; Dedoni, Maurizio; Mazza, Antonio; Pession, Andrea; Giannini, Anna Maria; Salvini, Filippo; Dodi, Icilio; Carloni, Ines; Cazzato, Salvatore; Tovo, Pier Angelo; de Martino, Maurizio; Galli, Luisa. - In: BMC INFECTIOUS DISEASES. - ISSN 1471-2334. - 22:1(2022). [10.1186/s12879-022-07026-w]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2933074
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 1
social impact